Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 20/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 16/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 15/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787008 | 0.90 | ADRA1A (0.52) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL6786714 | 0.89 | ADRA1A (0.61) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL6785313 | 0.86 | ADRA1A (0.52) | ADRA1AADRA1DADRA1B | |
| SCHEMBL6784825 | 0.78 | ADRA1A (0.52) | ADRA1AADRA1DADRA1B | |
| SCHEMBL8554552 | 0.77 | ADRA1A (0.53) | ADRA1AADRA1DADRA1B | |
| SCHEMBL6785447 | 0.77 | ADRA1A (0.55) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL6785334 | 0.77 | ADRA1A (0.49) | ADRA1AADRA1DADRA1B | |
| SCHEMBL7237695 | 0.74 | ADRA1A (0.64) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL8642356 | 0.74 | ADRA1A (0.51) | ADRA1AADRA1DADRA1B | |
| SCHEMBL7971293 | 0.74 | ADRA1A (0.64) | ADRA1AADRA1DADRA1BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727257-B1 | HYPOTENSIVE AGENTS FOR INTRAOCULAR PRESSURE; ANTICHOLESTEROL AGENTS; RELAXING URINARY TRACT TISSUE; BENIGN PROSTATIC HYPERPLASIA, IMPOTENCY, AND CARDIOVASCULAR DISORDERS; ANTIARRHYTHMIA AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-24 | — | — | US | disclosed |
| US-6268369-B1 | ALPHA SUB 1 INHIBITORS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-6248747-B1 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH ANTAGONISTS SELECTIVE FOR CLONED HUMAN ALPHA-1C RECEPTORS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-06-19 | — | — | US | disclosed |
| US-6245773-B1 | BENIGN PROSTATIC HYPERPLAMIA; REDUCTION OF INTRAOCULAR PRESSURE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-06-12 | — | — | US | disclosed |
| US-5942517-A | ANTAGONIST OF ALPHA(1C) RECEPTORS; TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | ADRA1A 4/4885ADRA1D 3/4885ADRA1B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.